Amitoj Singh

Amitoj Singh

Auto-generated profile, based on publicly available information

Amitoj Singh

Sarver Heart Center, University of Arizona , Tucson, 1501 N Campbell Ave, Tucson, AZ 85724

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
LGLauren G. Gilstrap
Lauren G. Gilstrap
FDFrancesca Dominici
Francesca Dominici
YWYun Wang
Yun Wang
MEM. Samir El-Sady
M. Samir El-Sady
ASAmitoj Singh
Amitoj Singh
SDSharmila Dorbala
Sharmila Dorbala
Background: Cardiac amyloidosis is a substantially underdiagnosed disease, and contemporary estimates of the epidemiology of amyloidosis are lacking. This study aims to determine the incidence and prevalence of cardiac amyloidosis among Medicare beneficiaries from 2000 to 2012. Methods and Results: Medicare beneficiaries were counted in the prevalence cohort in each year they had (1) ≥1 principal or secondary International Classification of Diseases , Ninth Revision code for amyloidosis and (2) ≥1 principal or secondary International Classification of Diseases, Ninth Revision code for heart failure or cardiomyopathy within 2 years after the systemic amyloidosis code. A beneficiary was counted in the incidence cohort only during the first year in which they met criteria. Primary outcomes included the prevalence and incidence of hospitalizations for cardiac amyloidosis. There were 4746 incident cases of cardiac amyloidosis in 2012 and 15 737 prevalent cases in 2012. There was also a significant increase in the prevalence rate (8 to 17 per 100 000 person-years) and incidence rate (18 to 55 per 100 000 person-years) from 2000 to 2012, most notable after 2006. Incidence and prevalence increased substantially more among men, the elderly, and in blacks. Conclusions: The incidence and prevalence rates of cardiac amyloidosis are higher than previously thought. The incidence and prevalence rates of cardiac amyloidosis among hospitalized patients have increased since 2000, particularly among specific patient subgroups and after 2006, suggesting improved amyloidosis awareness and higher diagnostic rates with noninvasive imaging. In light of these trends, cardiac amyloidosis should be considered during the initial work up of patients ≥65 years old hospitalized with heart failure.

7 December 2017 in Cardiology and Therapy
Verified
Journal Article
Open access
PDF file
ASAmitoj Singh
Amitoj Singh
SSSajeev Saluja
Sajeev Saluja
AKAkshat Kumar
Akshat Kumar
SASahil Agrawal
Sahil Agrawal
MTMunveer Thind
Munveer Thind
JSJamshid Shirani
Jamshid Shirani
The recreational use of cannabis has sharply increased in recent years in parallel with its legalization and decriminalization in several countries. Commonly, the traditional cannabis has been replaced by potent synthetic cannabinoids and cannabimimetics in various forms. Despite overwhelming public perception of the safety of these substances, an increasing number of serious cardiovascular adverse events have been reported in temporal relation to recreational cannabis use. These have included sudden cardiac death, vascular (coronary, cerebral and peripheral) events, arrhythmias and stress cardiomyopathy among others. Many of the victims of these events are relatively young men with few if any cardiovascular risk factors. However, there are reasons to believe that older individuals and those with risk factors for or established cardiovascular disease are at even higher danger of such events following exposure to cannabis. The pathophysiological basis of these events is not fully understood and likely encompasses a complex interaction between the active ingredients (particularly the major cannabinoid, Δ9-tetrahydrocannabinol), and the endo-cannabinoid system, autonomic nervous system, as well as other receptor and non-receptor mediated pathways. Other complicating factors include opposing physiologic effects of other cannabinoids (predominantly cannabidiol), presence of regulatory proteins that act as metabolizing enzymes, binding molecules, or ligands, as well as functional polymorphisms of target receptors. Tolerance to the effects of cannabis may also develop on repeated exposures at least in part due to receptor downregulation or desensitization. Moreover, effects of cannabis may be enhanced or altered by concomitant use of other illicit drugs or medications used for treatment of established cardiovascular diseases. Regardless of these considerations, it is expected that the current cannabis epidemic would add significantly to the universal burden of cardiovascular diseases.

1 March 2018 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
SASahil Agrawal
Sahil Agrawal
LGLohit Garg
Lohit Garg
MSMahek Shah
Mahek Shah
MAManyoo Agarwal
Manyoo Agarwal
BPBrijesh Patel
Brijesh Patel
NKNavin K. Kapur
Navin K. Kapur
Background: Early readmissions contribute significantly to heart failure–related morbidity and negatively affect quality of life. Data on left ventricular assist device (LVAD)–related 30-day readmissions are scarce and limited to small studies. Methods and Results: Patients undergoing LVAD implantation between January 2013 and November 2014 who survived the index hospitalization were identified in the Nationwide Readmissions Database. We analyzed the incidence, predictors, causes, and costs of 30-day readmissions. Of 2510 LVAD recipients, 788 (31%) were readmitted within 30 days. Length of index hospitalization ≥31 days (hazard ratio [HR], 1.26; 95% confidence interval [CI], 1.07–1.50) and female sex (HR, 1.19; 95% CI, 1.01–1.42) were associated with a higher risk of 30-day readmission, whereas private insurance (HR, 0.83; 95% CI, 0.70–0.99), pre-LVAD use of short-term mechanical circulatory support (HR, 0.53; 95% CI, 0.29–0.98), and discharge to a short-term hospital facility (HR, 0.41; CI, 0.21–0.78) were associated with a lower risk. Cardiac causes accounted for 23.8% of readmissions: heart failure (13.4%) and arrhythmias (8.1%). Noncardiovascular causes accounted for 76.2% of readmissions: infection (30.2%), bleeding (17.6%), and device-related causes (8.2%). Mean length of stay for readmission was 10.7 days (median, 6 days), and average hospital cost per readmission was $34 948±2457. Conclusions: Early readmissions are frequent after LVAD implantation even in contemporary times. Preimplant identification of high-risk patients, and a protocol-driven follow-up using a multidisciplinary approach will be needed to reduce readmissions and improve outcomes.

16 March 2017 in Clinical Cardiology
Verified
Journal Article
Closed access
PDF file
NBNirmanmoh Bhatia
Nirmanmoh Bhatia
SASahil Agrawal
Sahil Agrawal
AGAakash Garg
Aakash Garg
DMDivyanshu Mohananey
Divyanshu Mohananey
ASAbhishek Sharma
Abhishek Sharma
JSJamshid Shirani
Jamshid Shirani

2 November 2018 in Journal of Nuclear Cardiology
Verified
Journal Article
Closed access
PDF file
PBPaco E. Bravo
Paco E. Bravo
ASAmitoj Singh
Amitoj Singh
MCMarcelo F. Di Carli
Marcelo F. Di Carli
RBRon Blankstein
Ron Blankstein

1 November 2016 in International Journal of Cardiology
Verified
Journal Article
Closed access
SASahil Agrawal
Sahil Agrawal
LGLohit Garg
Lohit Garg
SNSudip Nanda
Sudip Nanda
ASAbhishek Sharma
Abhishek Sharma
NBNirmanmoh Bhatia
Nirmanmoh Bhatia
JSJamshid Shirani
Jamshid Shirani